- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma posted strong FY25 results: Revenue up 11.99% to ₹9,151 Cr, Net Profit surged 5x to ₹91.13 Cr, with net debt/EBITDA improving to 2.7x. The company significantly cut Scope 1&2 emissions by 6% YoY, boosted renewable energy 7.8%, and achieved zero hazardous waste to landfill. Plus, 36 regulatory inspections cleared.